Literature DB >> 2069370

Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection.

P Van der Auwera1, F Meunier, S Ibrahim, L Kaufman, M P Derde, P M Tulkens.   

Abstract

The pharmacologic parameters and toxicity of netilmicin (6 mg/kg/day) given once daily (qd) or thrice daily (tid) for the treatment of urinary tract infections were studied in a randomized prospective study of 60 cancer patients. The overall efficacy was 96%. Nephrotoxicity, assessed by the measure of urinary excretion of phospholipids, was lower for the patients receiving the qd regimen than for those receiving the tid regimen. Elevation of serum creatinine (20% over baseline) occurred in one patient receiving the qd regimen and in three receiving the tid regimen. Cochleotoxicity, assessed by pure-tone audiometry (250 to 18,000 Hz) occurred in one patient receiving the qd regimen and none receiving the tid regimen. Concentrations in sera were measured on days 1 and 5. No significant accumulation was observed in either group. Median serum bactericidal titers, expressed as reciprocal values (percentage of the sera with a titer greater than or equal to 8), were measured against 25 test organisms in samples collected 6 h after the administration of netilmicin and were, for the qd group, 16 (82%) against members of the family Enterobacteriaceae and less than 2 (8%) against Pseudomonas aeruginosa, and for the tid group, 4 (57%) against members of the Enterobacteriaceae and less than 2 (0%) against P. aeruginosa. The rate of killing in serum was rapid (2 to 3 log in 2 h against P. aeruginosa; 3 to 5 log in 2 h against members of the Enterobacteriaceae) and correlated with the sampling time and hence the concentration in serum of netilmicin. The duration of the postantibiotic effect in serum depended also on the strain and the sampling time of the serum.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2069370      PMCID: PMC245072          DOI: 10.1128/AAC.35.4.640

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone.

Authors:  E W ter Braak; P J de Vries; K P Bouter; S G van der Vegt; G C Dorrestein; J W Nortier; A van Dijk; R P Verkooyen; H A Verbrugh
Journal:  Am J Med       Date:  1990-07       Impact factor: 4.965

2.  Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia.

Authors:  J P Sculier; J Klastersky
Journal:  Am J Med       Date:  1984-03       Impact factor: 4.965

3.  The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  J Infect Dis       Date:  1984-03       Impact factor: 5.226

4.  Value of serum tests in combined drug therapy of endocarditis.

Authors:  T A Drake; C J Hackbarth; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

Review 5.  Drug therapy. Serum bactericidal activity as a monitor of antibiotic therapy.

Authors:  J S Wolfson; M N Swartz
Journal:  N Engl J Med       Date:  1985-04-11       Impact factor: 91.245

6.  Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests.

Authors:  L B Reller; C W Stratton
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

7.  Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  Am J Med       Date:  1984-10       Impact factor: 4.965

8.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

Review 9.  Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982.

Authors:  G Kahlmeter; J I Dahlager
Journal:  J Antimicrob Chemother       Date:  1984-01       Impact factor: 5.790

10.  The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure.

Authors:  W M Bennett; C E Plamp; D N Gilbert; R A Parker; G A Porter
Journal:  J Infect Dis       Date:  1979-10       Impact factor: 5.226

View more
  14 in total

1.  Once-daily dosing of aminoglycosides.

Authors:  J Blaser; C König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-12       Impact factor: 3.267

2.  Once-daily aminoglycoside therapy: potential ototoxicity.

Authors:  C Singer; C Smith; D Krieff
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

3.  In vivo antibacterial effects of simulated human serum profiles of once-daily versus thrice-daily dosing of amikacin in a Serratia marcescens endocarditis experimental model.

Authors:  D Bugnon; G Potel; Y Q Xiong; J Caillon; M F Kergueris; P Le Conte; D Baron; H Drugeon
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 4.  Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations.

Authors:  K Mörike; M Schwab; U Klotz
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 5.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Easier monitoring of aminoglycoside therapy with once-daily dosing schedules.

Authors:  J M Prins; R P Koopmans; H R Büller; E J Kuijper; P Speelman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-06       Impact factor: 3.267

7.  Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model.

Authors:  Y Q Xiong; J Caillon; M F Kergueris; H Drugeon; D Baron; G Potel; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

8.  Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children.

Authors:  A Viganò; N Principi; L Brivio; P Tommasi; P Stasi; A D Villa
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 9.  Aminoglycosides--50 years on.

Authors:  E J Begg; M L Barclay
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

Review 10.  What is the evidence for once-daily aminoglycoside therapy?

Authors:  M L Barclay; E J Begg; K G Hickling
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.